Treatment of Acute Hepatitis C-How to Explain the Differences?

Gastroenterology

Volumn 131, Issue 2, 2006, Pages 682-683

  Wedemeyer, Heiner ^a   Cornberg, Markus ^a   Wiegand, Johannes ^a   Jäckel, Elmar ^a   Manns, Michael P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2B;

ACUTE HEPATITIS; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; NONHUMAN; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; RELAPSE; UNSPECIFIED SIDE EFFECT;

EID: 33746580846     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.06.043     Document Type: Letter

References (11)

1. Kamal S.M., Fouly A.E., Kamel R.R., Hockenjos B., Al Tawil A., Khalifa K.E., He Q., Koziel M.J., El Naggar K.M., Rasenack J., and Afdhal N.H. Peginterferon Alfa-2b therapy in acute hepatitis C. impact of onset of therapy on sustained virologic response. Gastroenterology 130 (2006) 632-638
2. Broers B., Helbling B., Francois A., Schmid P., Chuard C., Hadengue A., and Negro F. Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 42 (2005) 323-328
3. Wiegand J., Buggisch P., Boecher W., Zeuzem S., Gelbmann C.M., Berg T., Kauffmann W., Kallinowski B., Cornberg M., Jaeckel E., Wedemeyer H., and Manns M.P. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection. the HEP-NET acute-HCV-II study. Hepatology 43 (2006) 250-256
4. Lehmann M., Meyer M.F., Monazahian M., Tillmann H.L., Manns M.P., and Wedemeyer H. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol 73 (2004) 387-391
5. De Carli G., Puro V., and Ippolito G. Risk of hepatitis C virus transmission following percutaneous exposure in healthcare workers. Infection 31 Suppl 2 (2003) 22-27
6. Puro V., Petrosillo N., Ippolito G., Aloisi M.S., Boumis E., and Rava L. Occupational hepatitis C virus infection in Italian health care workers. Italian Study Group on Occupational Risk of Bloodborne Infections. Am J Public Health 85 (1995) 1272-1275
7. Kamal S., El Tawil A., He Q., El Sayed K.K., Hafez A., Koziel M., Ismail A., Rasenack J., and Madwar M. Peginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4. impact of treatment duration on sustained virological response. Hepatology 40 (2004) 322A
8. Kamal S., Ismail A., Al Tawil A., Hakam S., He Q., Rasenack J., Efouly A., and Madwar M. Peginterferon alfa 2-B therapy for 8 weeks in acute hepatitis C genotypes 1 and 4. a pilot study. Gastroenterology 128 (2005) A683
9. Kamal S., He Q., Al Tawil A., Khalifa K., Hakam S., Saleh W., Omar M., Rasenack J., Koziel M., and Madwar M. Peginterferon alpha-2b therapy in acute hepatitis C. impact of onset and duration of therapy on sustained virologic response. J Hepatol 42 (2005) 8
10. Kamal S.M., Moustafa K.N., Chen J., Fehr J., Abdel Moneim A., Khalifa K.E., Gohary L.A., Ramy A.H., Madwar M.A., Rasenack J., and Afdhal N.H. Duration of peginterferon therapy in acute hepatitis C. a randomized trial. Hepatology 43 (2006) 923-931
11. Manns M.P., Meyer S., and Wedemeyer H. The German network of excellence for viral hepatitis (hep-net). Hepatology 38 (2003) 543-554